Webcast replay
Recorded on 26th April 2023 at 12pm (AEST).
Prescient Therapeutics (ASX: PTX) CEO and MD Steven Yatomi-Clarke discusses how Prescient’s broad portfolio of well advanced assets developed with world-leading partners including Yale, UPenn, Oxford, MDAnderson & Peter MacCallum.
Feature Speakers
STEVEN YATOMI-CLARKE
CEO and Managing Director
Steven took over as CEO of Prescient Therapeutics in 2016 and has overseen its progression from start-up phase. Steven manages a team in Australia and the US and has been instrumental in strategy development; licensing; initiating and managing clinical trials; fundraising and business development. He has been a collaborator on various immunotherapy research projects.
